Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 100 Breast Neoplasms 74 Fallopian Tube Neoplasms 47 Multiple Myeloma 32 Carcinoma, Ovarian Epithelial 27 Neoplasms 23 Lymphoma 15 Triple Negative Breast Neoplasms 12 Sarcoma 12 Recurrence 12 Neoplasm Metastasis 12 Lymphoma, Large B-Cell, Diffuse 10 Lymphoma, Non-Hodgkin 8 Hodgkin Disease 8 Neoplasms, Plasma Cell 6 Prostatic Neoplasms 5 Burkitt Lymphoma 5 Solid Tumors 4 Sarcoma, Kaposi 4 Sarcoma, Ewing 4 Pancreatic Neoplasms 4 Lymphoma, T-Cell, Peripheral 4 Lymphoma, Mantle-Cell 4 Leiomyosarcoma 4 Endometrial Neoplasms 4 Carcinoma 4 Breast Neoplasms, Male 4 Uterine Cervical Neoplasms 3 Rhabdomyosarcoma 3 Peritoneal Neoplasms 3

Interventions

atezolizumab 2 Gemcitabine 2 Cell Count 2 valrubicin 1 tretazicar 1 pembrolizumab 1 liposomal doxorubicin 1 fludarabine phosphate 1 fludarabine 1 enadenotucirev 1 Vaccines 1 Tumor Necrosis Factor-alpha 1 Radiotherapy 1 Oncolytic Virotherapy 1 Mitomycin 1 Interferons 1 Interferon-beta 1 Immune Checkpoint Inhibitors 1 Genetic Engineering 1 Endostatins 1 Capecitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenoviridae Infections × liposomal doxorubicin × Clear all

NCT05271318 2026-05-05

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Active not recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡